Population Group
FDA Institutes Stricter, Targeted COVID Vaccine Policy, Moving Away from ‘One-Size-Fits-All’ Approach
FDA; COVID-19; vaccine policy; vaccine eligibility; clinical trials; high-risk groups; elderly; policy change; public health
FDA Approves Novavax COVID Vaccine After Delay, Limits Use to Smaller High-Risk Population
Novavax; FDA approval; COVID-19 vaccine; Nuvaxovid; restricted population; protein-based vaccine; older adults; underlying health conditions
FDA, CDC call for pause of chikungunya shot rollout in older adults
Ixchiq vaccine, chikungunya, safety concerns, older adults, FDA, CDC, pause recommendation, adverse events
ElevAAte and the push for East Asian American leaders in biopharma
ElevAAte, biopharma, East Asian American, Leadership, leaders, Asian Americans, Mentorships, East Asian Americans, Ken Song
FDA frees Amgen’s phase 1 obesity asset from clinical trial hold
Obesity, United States Food and Drug Administration, Amgen, MariTide, Study on Hold, Participant
FDA withdraws two final guidances, pulls compliance deadlines for bone allograft makers
United States Food and Drug Administration, Allogeneic bone graft, Mycobacterium tuberculosis, guidances, Disease Outbreaks, standards characteristics
France pauses chikungunya vaccinations in the elderly after patient death
Vaccines, Chikungunya Fever, Elderly (population group), Adverse event, France, Latex Fixation Tests, Reunion Island, Disease Outbreaks, Age, older, Vaccination
New NIH grant rules override the Civil Rights Act of 1964, barring recipients from DEI activities
United States National Institutes of Health, recipients, NIH, Policy, Diversity, Changing, Condition, civil, federal, civil, protections, recipients, Israeli (population group), Civil Rights Act, 1964
Lilly continues full-court press against breast cancer with women’s March Madness event sponsorships
Eli Lilly, Woman, Madness, Malignant neoplasm of breast, Event, Awareness, Basketball game
Biotech Restructuring and European Regulatory Setbacks
LifeMine Therapeutics, layoffs, PTC Therapeutics, Translarna, Duchenne muscular dystrophy, European Commission, regulatory decision